Takeda completes raft of settlements in US generic Actos litigation
This article was originally published in Scrip
Takeda has now reached settlements with all of the defendants in patent infringement litigation that it had brought against filers of US ANDAs for generic versions of its big-selling oral antidiabetic, Actos (pioglitazone), and two combinations of this.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.